Viatris faces Indore plant securities class action and derivative suits in two federal courts

Viatris (Nasdaq: VTRS) disclosed in its 10-Q filed August 6, 2026 that a putative securities class action over its Indore, India manufacturing facility is pending in the U.S. District Court for the Western District of Pennsylvania, along with derivative suits in that court and in the U.S. District Court for the District of Delaware. The class action was filed in April 2025 and, per the 10-Q, has been amended twice, in September 2025 and March 2026. The derivative suits began in November 2025. The 10-Q gives no case numbers.

The class action defendants are Viatris and "certain of the Company's current and former officers". The derivative suits are brought against certain current and former officers and directors, with Viatris as a nominal defendant. The 10-Q does not name any individual.

The case

The amended class action complaint alleges that the defendants made false or misleading statements or omissions of material fact, in violation of federal securities laws, in connection with disclosures about regulatory issues and actions concerning the Indore facility. The plaintiffs seek to certify a class of purchasers of Viatris securities between February 28, 2024 and February 26, 2025. They seek damages, costs and fees.

The derivative complaints allege that the defendants failed to ensure Viatris made truthful and accurate statements in connection with the disclosures at issue in the class action. They assert violations of federal securities laws and claims for breach of fiduciary duty, waste of corporate assets and unjust enrichment. The plaintiffs seek damages, disgorgement, restitution, equitable relief, costs and fees.

For context, the 10-Q says the FDA inspected the Indore oral finished dose facility in 2024 and then issued a warning letter and an import alert. The import alert affects 11 products that will not be accepted into the U.S. until the warning letter is lifted.

Defendants

The 10-Q does not list the individual defendants. Viatris's 10-K filed February 28, 2024 shows Scott A. Smith as chief executive officer and Sanjeev Narula as chief financial officer. Viatris's 10-K filed February 27, 2025 shows Smith as chief executive officer and Theodora Mistras as chief financial officer. The 2025 proxy statement, filed October 24, 2025, says Mistras has served as CFO since March 1, 2024. The filings do not say whether any of them is a defendant.

For the derivative suits, that proxy statement says the board had 15 directors and nominated 13: W. Don Cornwell, Frank D'Amelio, JoEllen Lyons Dillon, Elisha Finney, Leo Groothuis, Melina Higgins, James M. Kilts, Richard Mark, Mark Parrish, Michael Severino, David Simmons, Scott A. Smith and Rogério Vivaldi Coelho. Harry Korman and Rajiv Malik were not nominated. The filings do not say which directors are named.

Where it stands

The 10-Q reports no ruling, schedule or settlement for the Indore class action or the derivative suits. The class action has been through two amended complaints. The 10-Q does not say whether Viatris has moved to dismiss.

Why it matters to shareholders

Viatris says it has a total accrual of approximately $60.0 million related to "these matters" at June 30, 2026. That paragraph closes the 10-Q's securities litigation section, which also covers the Mylan N.V. class action Viatris agreed in February 2026 to settle for $60 million. The 10-Q does not break the accrual out by case. It says additional losses are reasonably possible but cannot be reasonably estimated. Viatris also expects more legal and professional fees and says the ultimate amount paid could have a material effect on its business, cash flows, ability to pay dividends or repurchase shares, and stock price.

Viatris says it maintains insurance for these matters. The only insurance figure it gives is a $58.0 million receivable for the Mylan N.V. class action, where management has determined the majority of the losses are covered.

Related matters

The court has approved the Mylan N.V. settlement, and that case is closed. A 2023 class action over Viatris's projected performance and biosimilars business was dismissed in September 2024, and the derivative suits that followed it were dropped by the plaintiffs in April 2026.

Report an error

Companies in this story

VTRSViatris Inc.NASDAQ · United StatesOpen the starter desk